NASM Launches New Understanding Weight Loss Medications Course
Based Review of GLP-1/GIP Agonists for Fitness and Wellness ProfessionalsGilbert, AZ, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The ...
Psychology Today12d
New Weight Loss Medications May Help Treat Addiction
New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...
AOL13d
This Weight Loss Stock Could Soar Over 220%, According to Wall Street. Time to Buy?
which is a dual GLP-1/GIP agonist that is being tested to treat obesity. (GIP is glucose-dependent insulinotropic polypeptide.) In my opinion, Wall Street is intrigued by Viking because the ...
Yahoo Finance7d
Down 65%, Is Viking Therapeutics Stock a Buy on the Dip?
Viking Therapeutics stock jumped higher last year because it looks like a dual GLP-1/GIP agonist it's developing could outperform tirzepatide. The injectable version of the candidate, tentatively ...
Viking Therapeutics initiated with a Neutral at Citi
Citi analyst David Lebowitz initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $38 price target Viking’s VK2735 is an ...
Down 65%, Is Viking Therapeutics Stock a Buy on the Dip?
Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...
Psychology Today13d
New Weight Loss Medications May Help Treat Addiction
GLP-1 agonists and glucose-dependent insulinotropic polypeptide (GIP) agonists currently prescribed for weight-related conditions include Semaglutide (brand names Ozempic, Wegovy) and Tirzepatide ...